Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (268)	11/19/2001 9:29:40 AM
From: Icebrg	Read Replies (1) \| Respond to of 1022

GZMO and Kirin: You can't win them all. I wonder what Medarex feels about this? As far as I know, Kirin and Medarex have cross-licensed their respective technologies. So, in principle Medarex should have been able to offer the same thing. Perhaps they felt the costs would be too high with milestones to be paid and a research program to be funded. MEDX's programs are normally straight 50/50 arrangements with MEDX providing the mouse and the partner the target. Ice